Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2015 1
2020 3
2021 3
2024 2
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.
Ahmed N, Thiruvengadam SK, Hamadani M, Hu ZH, Grover N, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang M, Kim S, Bye M, Kharfan-Dabaja MA, Sauter C, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan B, Nunes A, Dalton D, Kloos I, Lee D, Xu H, Pasquini MC, Herrera AF. Ahmed N, et al. Blood Adv. 2025 Oct 28;9(20):5382-5396. doi: 10.1182/bloodadvances.2024015014. Blood Adv. 2025. PMID: 40706035 Free PMC article.
Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with …
Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma ( …
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS. Shah NN, et al. J Clin Oncol. 2025 Jul 10;43(20):2285-2295. doi: 10.1200/JCO-24-02158. Epub 2025 Mar 31. J Clin Oncol. 2025. PMID: 40163793 Clinical Trial.
To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells as part of a phase I/II clinical trial in relapsed, refractory (R/R) MCL (ClinicalTrials.gov identifier: …
To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual targeted lentiviral anti-CD20/anti-CD19 …
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.
Mirza AS, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Abid MB, Afrough A, Ahmed S, Badar T, Barba P, Bhatt VR, Brown VI, Dahiya S, Deol A, Epperla N, Ganguly S, Grover NS, Hashmi H, Hashmi S, Hematti P, Hildebrandt GC, Hill JM Jr, Hossain NM, Ibrahim U, Johnson PC, Kharfan-Dabaja MA, Krem MM, Lekakis LJ, Maziarz RT, Murthy HS, Riedell PA, Salas MQ, Shouse G, Strouse C, Thakar MS, Turtle CJ, Woolfrey A, Wudhikarn K, Yared JA, Pasquini MC, Gowda L. Mirza AS, et al. Blood Neoplasia. 2025 Nov 25;3(2):100187. doi: 10.1016/j.bneo.2025.100187. eCollection 2026 May. Blood Neoplasia. 2025. PMID: 41867486 Free PMC article.
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Geethakumari PR, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse C, Turtle CJ, Vallurupalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror M. Greenbaum U, et al. Blood Adv. 2026 Jan 13;10(1):217-227. doi: 10.1182/bloodadvances.2024015599. Blood Adv. 2026. PMID: 40811818 Free PMC article.
Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis.
Farhadfar N, Rashid N, Chen K, DeVos J, Wang T, Ballen K, Beitinjaneh A, Bhatt VR, Hamilton BK, Hematti P, Gadalla SM, Solomon SR, El Jurdi N, Lee CJ, MacMillan ML, Rangarajan HG, Schoemans H, Sharma A, Spellman SR, Wingard JR, Lee SJ. Farhadfar N, et al. Blood Adv. 2024 Sep 24;8(18):4963-4976. doi: 10.1182/bloodadvances.2024013074. Blood Adv. 2024. PMID: 38776400 Free PMC article.
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.
Zinter MS, Brazauskas R, Strom J, Chen S, Bo-Subait S, Sharma A, Beitinjaneh A, Dimitrova D, Guilcher G, Preussler J, Myers K, Bhatt NS, Ringden O, Hematti P, Hayashi RJ, Patel S, De Oliveira SN, Rotz S, Badawy SM, Nishihori T, Buchbinder D, Hamilton B, Savani B, Schoemans H, Sorror M, Winestone L, Duncan C, Phelan R, Dvorak CC. Zinter MS, et al. Blood Adv. 2024 Feb 27;8(4):1002-1017. doi: 10.1182/bloodadvances.2023011002. Blood Adv. 2024. PMID: 38127268 Free PMC article.
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, Ahmed TF, Ahmed Z, Khurana S, Ahmed N, Balusu R, Singh AK, Hematti P, Callander NS, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Transplant Cell Ther. 2021 Oct;27(10):877.e1-877.e8. doi: 10.1016/j.jtct.2021.07.012. Epub 2021 Jul 18. Transplant Cell Ther. 2021. PMID: 34284148 Free article.
Quality evaluation was done using the National Institutes of Health quality assessment tool. Pooled analysis was done using the R 'meta' package, and proportions with 95% confidence intervals (CIs) were computed. ...
Quality evaluation was done using the National Institutes of Health quality assessment tool. Pooled analysis was done using the R 'me …
Preclinical Evaluation of the Safety and Efficacy of Cryopreserved Bone Marrow Mesenchymal Stromal Cells for Corneal Repair.
Putra I, Shen X, Anwar KN, Rabiee B, Samaeekia R, Almazyad E, Giri P, Jabbehdari S, Hayat MR, Elhusseiny AM, Ghassemi M, Mahmud N, Edward DP, Joslin CE, Rosenblatt MI, Dana R, Eslani M, Hematti P, Djalilian AR. Putra I, et al. Transl Vis Sci Technol. 2021 Aug 12;10(10):3. doi: 10.1167/tvst.10.10.3. Transl Vis Sci Technol. 2021. PMID: 34383879 Free PMC article.
14 results